- Home
- KNSA vs TSLX Comparison
KNSA vs TSLX Comparison
Compare KNSA & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- TSLX
- Stock Information
- Founded
- KNSA 2015
- TSLX 2010
- Country
- KNSA United Kingdom
- TSLX United States
- Employees
- KNSA N/A
- TSLX N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- TSLX Investment Managers
- Sector
- KNSA Health Care
- TSLX Finance
- Exchange
- KNSA Nasdaq
- TSLX Nasdaq
- Market Cap
- KNSA 1.9B
- TSLX 2.1B
- IPO Year
- KNSA 2018
- TSLX 2014
- Fundamental
- Price
- KNSA $33.28
- TSLX $24.29
- Analyst Decision
- KNSA Strong Buy
- TSLX Strong Buy
- Analyst Count
- KNSA 6
- TSLX 9
- Target Price
- KNSA $40.83
- TSLX $23.28
- AVG Volume (30 Days)
- KNSA 711.9K
- TSLX 423.8K
- Earning Date
- KNSA 07-29-2025
- TSLX 07-30-2025
- Dividend Yield
- KNSA N/A
- TSLX 8.55%
- EPS Growth
- KNSA N/A
- TSLX N/A
- EPS
- KNSA 0.07
- TSLX 2.01
- Revenue
- KNSA $529,332,000.00
- TSLX $474,291,000.00
- Revenue This Year
- KNSA $37.21
- TSLX N/A
- Revenue Next Year
- KNSA $6.10
- TSLX N/A
- P/E Ratio
- KNSA $504.35
- TSLX $12.07
- Revenue Growth
- KNSA 56.18
- TSLX 0.15
- 52 Week Low
- KNSA $17.82
- TSLX $18.58
- 52 Week High
- KNSA $33.98
- TSLX $25.17
- Technical
- Relative Strength Index (RSI)
- KNSA 65.73
- TSLX 53.20
- Support Level
- KNSA $31.78
- TSLX $23.74
- Resistance Level
- KNSA $33.66
- TSLX $24.46
- Average True Range (ATR)
- KNSA 1.26
- TSLX 0.41
- MACD
- KNSA 0.24
- TSLX -0.01
- Stochastic Oscillator
- KNSA 90.63
- TSLX 57.50
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.